Application/Control Number: 10/615,126

Art Unit: 1626

1. Cancel claims 63, 65 and 66

- 2. <u>In Claim 56</u>: delete "and" and insert ---or--- after "claims 1, 4, 5, 6," and before "7, wherein" on page 16 of 22.
- 3. <u>In Claim 57</u>: delete "and" and insert ---or--- after "claims 1, 4, 5, 6," and before "7, wherein" on page 16 of 22.
- 4. <u>In Claim 67</u>: **delete** "and" and **insert** ---or--- after "claims 1, 4, 5, 6," and before "7, wherein" on page 19 of 22.
- 5. <u>In Claim 64</u>: delete "for treating a disorder selected from the group consisting of inflammatory disorders, endocrine disorders; collagen diseases; dermatologic disease; allergic states; ophthalmic diseases; respiratory diseases; hematologic disorders; neoplastic diseases; edematous states; and gastrointestinal diseases in a mammal" after "composition" and before "comprising" on p. 18 of 22.

llul 5906

6. <u>In Claim 64</u>: delete "or prodrug thereof" before "or a salt" and a pharmaceutically" on p. 18 of 22.

IV. REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The instant invention is drawn to the compound of formula (I), phenanthrene derivatives. The instant invention appears to be free of the art of record. The closest prior art reference of record is Chen et al., EP 1097709 A2. The instant invention is neither anticipated nor rendered obvious by the prior art of record because the instant invention of formula (I) R4 is either -OH or NR¹⁴R¹⁵. Although the